- Home
- MUA vs IRWD Comparison
MUA vs IRWD Comparison
Compare MUA & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MUA | IRWD |
|---|---|---|
| Founded | N/A | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 666.0M | 713.8M |
| IPO Year | 1994 | 2009 |
Fundamental Metrics
Financial Performance| Metric | MUA | IRWD |
|---|---|---|
| Price | $9.70 | $4.30 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 375.4K | ★ 1.5M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1400.00 |
| EPS | N/A | ★ 0.55 |
| Revenue | N/A | ★ $298,276,000.00 |
| Revenue This Year | N/A | $57.95 |
| Revenue Next Year | N/A | $4.39 |
| P/E Ratio | ★ N/A | $7.69 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $9.62 | $1.26 |
| 52 Week High | $11.48 | $5.78 |
Technical Indicators
Market Signals| Indicator | MUA | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 33.59 | 55.15 |
| Support Level | N/A | $3.89 |
| Resistance Level | $10.87 | $4.52 |
| Average True Range (ATR) | 0.09 | 0.17 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 17.23 | 73.15 |
Price Performance
Historical ComparisonAbout MUA Blackrock MuniAssets Fund Inc
Blackrock Muniassets Fund Inc is a closed-end fund. Its objective is to provide high current income exempt from U.S. federal income taxes by investing in a portfolio of medium- to lower-grade or unrated municipal obligations. The Fund invests more of its total assets in municipal bonds.
About IRWD Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.